Drug development targeting the glycogen synthase kinase-3/β (GSK-3/β)-mediated signal transduction pathway: Inhibitors of the Wnt//β-catenin signaling pathway as novel anticancer drugs

Fumi Takahashi-Yanaga, Toshiyuki Sasaguri

研究成果: Contribution to journalShort survey査読

59 被引用数 (Scopus)

抄録

Accumulating evidence suggests that the Wnt/β-catenin signaling pathway is often involved in oncogenesis and cancer development. Accordingly, a novel anticancer drug can be developed using inhibitors of this pathway. However, at present, there is no selective inhibitor of this pathway available as a therapeutic agent. Although all the components of the Wnt/β-catenin signaling pathway can be a target for drug development, glycogen synthase kinase-3? (GSK-3β), in particular, may be a good target because GSK-β? is an essential component of the pathway, and activation of this kinase results in the inhibition of the Wnt signaling pathway. We found that the differentiation-inducing factors (DIFs), putative morphogens for Dictyostelium discoideum, inhibit the Wnt/β-catenin signaling pathway via the activation of GSK-3β, resulting in the cell- cycle arrest of human cancer cell lines. In this review, we summarize our recent findings on the antiproliferative effect of DIFs and show the possibility for development of a novel anticancer drug from DIFs and their derivatives.

本文言語英語
ページ(範囲)179-183
ページ数5
ジャーナルJournal of Pharmacological Sciences
109
2
DOI
出版ステータス出版済み - 2009

All Science Journal Classification (ASJC) codes

  • 分子医療
  • 薬理学

フィンガープリント

「Drug development targeting the glycogen synthase kinase-3/β (GSK-3/β)-mediated signal transduction pathway: Inhibitors of the Wnt//β-catenin signaling pathway as novel anticancer drugs」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル